Colorless Liquid GS-441524 C12H13N5O4 CAS 1191237-69-0
- mojin
- China
- 7 days
- 500 ton/month
We are a company specializing in the production of GS-441524,
We have the following advantages :
1.We have a large number of production conditions every month to ensure fresh production dates for goods.
2.We are the manufacturing factory that will let you buy the highest quality products at the cheapest price.
3.If there is a quality problem in the goods, we have a complete production - sale - after-sales service, you can timely contact our after-sales personnel.
| Product name | GS441524 |
| CAS NO. | 1191237-69-0 |
| Appearance | Powder |
| Brand | mojin |
| Purity | 99% |
Purity: 97% | Package: 500 mg | CustNote: GS-441524 is an analog nucleotide inhibitor against feline infectious peritonitis virus (FIPV). EC50 is 0.78?uM. GS-441524 is also a metabolite and intermediate of Remdesivir.
Remdesivir, a nucleoside analogue, has antiviral activity with an EC50 value of 74 nM against SARS-CoV and MERS-CoV in HAE cells and 30 nM against murine hepatitis virus in delayed brain tumor cells.
On May 7, 2020, Japan approved Redesivir, developed by Gilead Technologies, as the country's first novel coronavirus treatment drug, which will be used to treat severe patients.
On October 22, 2020, the US Food and Drug Administration (FDA) approved Gilead Sciences' antiviral drug Remdesivir to treat hospitalized COVID-19 patients, becoming the first officially approved treatment for COVID-19 in the US.
On 20 November 2020, the World Health Organization (WHO) issued a statement saying that the use of the antiviral drug desivir is not recommended for hospitalized patients, no matter how severe their illness, because there is no evidence that it improves survival or reduces the need for ventilators
